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Objective. The purpose was to review cases of malpractice in head and neck cancer (HNC) in order to examine allegations
and outcomes of the litigation and to assess the implications for best practices in the clinical care of patients with HNC.
Materials and Methods. Three U.S. legal databases were accessed to assess the basis of the cases and the outcomes reported.
Results. Dental and medical health care providers are identified in cases with alleged failure to diagnose or delayed diagnosis.
In addition, inadequate prevention and management of oral complications of cancer therapy also may result in medicolegal
action. In the dental cases, the mean recovery was $1,033,500.11, and in medical cases, it was $2,828,639.20.
Conclusions. In addition to failure in the diagnosis of malignant disease, our review identified failure to properly prevent and
manage oral complications as potential causes of medicolegal actions. Evidence-based care with a multidisciplinary team may
promote diagnosis of disease and prevention and management of complications. (Oral Surg Oral Med Oral Pathol Oral Radiol
2015;119:177-186)Cancers in the head and neck region at early stages are
commonly associated with few symptoms, and when
symptoms are present, they may be minor and
nonspeciﬁc. Even advanced-stage cancers at initial
presentation may have few, minimal, or nonspeciﬁc
symptoms. Mucosal lesions may appear clinically
innocuous, presenting as red or white changes that may
mimic benign conditions and may not raise concerns in
the patient or the examiner. Establishment of a diag-
nosis is a process that requires the synthesis of a series
of events and observations ultimately including the
patient’s presentation in a health care environment.
Diagnosis can be completed following a comprehensive
patient history, thorough examination of the head and
neck and oral tissues, knowledge of variations of
normal, and an index of suspicion for ﬁndings that
could represent oral potentially malignant epithelial
lesions (PMEL), squamous cell carcinoma (SCC), or
other neoplasms, including those of salivary and
lymphoid origins, among others. Diagnosis requires
recognition of the abnormal, as well as appropriate and
accurate testing and interpretation of results. Upon
diagnosis, referral for appropriate cancer therapy andaCollaborative Member, Samuel Oschin Comprehensive Cancer
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Open access under CC BY-NC-ND license.prevention of common oral and other local complica-
tions of treatment following current standards of care
are necessary.
The diagnostic process presents the risk for delay or
misdiagnosis at each step from patient presentation to
tissue diagnosis. In cases of oral squamous cell carci-
noma and oropharyngeal squamous cell carcinoma,
delays in diagnosis of more than 1 month have been
reported to contribute to diagnosis of later-stages of
disease.1-3 However, other studies have not shown
statistically signiﬁcant associations between the stage of
disease and delay and the outcomes of therapy.4,5
A study evaluating time to treatment reported a mean
delay of referrals to specialists of 5.1 weeks and a mean
time to surgical treatment of 5.2 weeks and 10.3 weeks
for radiation therapy. However, patient delay from ﬁrst
symptom to diagnosis may be the cause of longest
delay; one study reported a mean delay of 4.9 months.6
Dentists may identify early symptoms or signs of
PMEL and head and neck cancer (HNC) more
commonly compared with physicians (72.5 % dentists,
physicians 40%).7,8 However, a study of dentists and
physicians found that only 58% of dentists reported
routinely examining patients for oral cancer, and phy-
sicians reported examining the mouth only whenStatement of Clinical Relevance
Medicolegal actions may occur due to alleged delay
or failure in diagnosis and with alleged failure to
prevent and manage oral complications of cancer
therapy and may involve dentists and/or physicians.
Following current guidelines for the detection and
diagnosis of cancer and for the management of oral
complications may reduce the risk.
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Table I. Summary of dental malpractice cases
Incident date Filing date Mediation/ trial date Primary diagnosis Malpractice liability Allegations
Outcome of case (value in 2012
dollars)
Apr-03 Dec-05 Settlement: Sep-06 Oral cancer Diagnosis Failure to diagnose; progression of disease Mediation $50,000 ($57,370)
N/A Oct-87 Settlement: Jan-88 Oral cancer Diagnosis Failure to diagnose; progression of disease $200,000 ($391,068)
N/A N/A Trial: May-84 Oral cancer Diagnosis Failure to diagnose; progression of disease $3,500,000 ($7,792,199)
Jul-93 N/A Trial: Dec-97 Oral cancer Diagnosis Failure to diagnose; lesion attributed to
inﬂammation
Defense prevailed ($0)
Oct-85 N/A Trial: Sep-90 Oral cancer Diagnosis Failure to diagnose oral cancer from X-rays Defense prevailed Past Medical:
$4000 ($7,079)
Oct-02 N/A Trial: May-06 Oral cancer Diagnosis Failure to diagnose; progression of disease $1,199,999 ($,376,886)
Aug-98 N/A Trial: Apr-02 Oral cancer Diagnosis Failure to diagnose, progression of disease $870,000 ($1,1168,663)
Jan-94 Oct-97 Settlement: Apr-98 Oral cancer Diagnosis Failure to diagnose; progression of disease;
facial disﬁgurement Defendant: Cancer
already advanced; patient negligence
Settlement: $1,000,000 ($1,419,123)
N/A N/A Trial:Mar-94 Oral cancer Diagnosis Failure to diagnose; progression of disease Settlement: $325,000 ($507,724)
Mar-07 N/A Settlement: Jan-10 Oral cancer Diagnosis Failure to diagnose; progression of disease Settlement: $500,000 ($530,407)
Mar-93 N/A Trial: Oct-98 Oral cancer Diagnosis Failure to diagnose; progression of disease;
clinician and pathologist
Settlement: $300,000 ($425,737)
Sep-86 N/A Trial: Jan-89 Oral cancer Diagnosis Failure to diagnose; progression of disease $1,098,054 ($2,048,375)
Jun-05 N/A Settlement: Apr-07 Oral cancer Diagnosis Failure to diagnose; progression of disease Settlement: $180,000 ($200,813)
Feb-88 N/A Trial: Nov-92 Oral cancer Diagnosis Failure to diagnose; progression of disease Settlement: $220,000 ($362,721)
Dec-88 N/A Trial: May-91 Oral cancer Diagnosis Failure to diagnose; pathologist and oral
surgeon
$1,300,000 ($2,207,871)
2005 N/A Trial: Jan-10 Oral cancer Diagnosis Failure to diagnose; progression of disease
Failure to refer for biopsy
Settlement: $500,000 ($528,030)
May-06 N/A Trial: 2009 Oral cancer Diagnosis Failure to diagnose; progression of disease Jury award: $150,000,750
State’s malpractice reduced to
$619,000
Total recovery $525,000
($563,525)
Jan-04 N/A Settlement: Apr-07 Oral cancer Diagnosis Failure to diagnose persisting lesion Settlement: $180,000 ($199,913)
Apr-02 N/A Settlement: Jun-05 Oral cancer Diagnosis Failure to diagnose; failure to submit excised
tissue for pathology
Settlement: $400,000 ($471,644)
Aug-98 N/A Trial: Apr-03 Oral cancer Diagnosis Failure to diagnose; progression of disease Defense prevailed ($0)
N/A N/A Trial: Nov-99 Oral cancer Diagnosis Failure to diagnose; more extensive surgery
and radiation with damage to salivary
glands
Defense prevailed ($0)
Dec-92 N/A Trial: Apr-98 Oral cancer Diagnosis Failure to diagnose; progression of disease. Defense prevailed ($0)
Jul-92 N/A Trial: Jan-98 Oral cancer Diagnosis Failure to diagnose; progression of disease
Defendant claimed biopsy recommended;
patient refused
Defense prevailed ($0)
Jul-93 N/A Trial Dec-97 Oral cancer Diagnosis Failure to diagnose; progression of disease Defense prevailed ($0)
Dec-86 N/A Trial: Jun-92 Oral cancer Diagnosis Failure to diagnose progression of disease
Defendant’s initial lesion diagnosed as
abscess was not associated with cancer
Defense prevailed ($0)
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Table I. Continued
Incident date Filing date Mediation/ trial date Primary diagnosis Malpractice liability Allegations
Outcome of case (value in 2012
dollars)
N/A N/A Trial: Dec-11 Osteonecrosis Diagnosis Delay in diagnosis of osteonecrosis Defense
claimed that standard of care was
maintained and earlier diagnosis did not
affect outcome
Defendant prevailed ($0)
Feb-08 N/A Settlement: Apr-12 Oral cancer Diagnosis Failure to diagnose; progression of disease Settlement: $800,000 ($800,000)
Dec-03 N/A Trial: Mar-11 Oral cancer Diagnosis Failure to diagnose oral cancer and
progression of disease, leading to death
Defense prevailed ($0)
Jun-02 N/A Trial: May-06 Oral cancer Diagnosis Failure to diagnose; progression of disease Defense prevailed ($0)
May-92 Jan-94 Trial: Jul-96 Osteoradionecrosis Informed consent Failure to inform osteonecrosis risk with
prior radiation and treatment options
Plaintiff: 49% negligent, $1,454,319
($2,144,096)
May-92 N/A Trial: Jul-96 Osteoradionecrosis Informed consent Failure to inform of risk of necrosis; failure
to refer for hyperbaric oxygen
$1,018,000 [51% defendant fault;
49% plaintiff’s] ($1,300,833)
Dec-04 N/A Trial: May-11 Osteonecrosis Informed consent Failure to disclose risk of osteonecrosis
associated with zoledronic acid before
extraction Defense claimed that labels
provided adequate explanation of risk
Defendant prevailed ($0)
Jun-03 N/A Trial: Apr-07 Oral cancer Informed consent; treatment Failure to inform of alternative procedures
and risk of trismus Failure to obtain clear
margins
Defense prevailed ($0)
Feb-05 N/A Trial: Jun-09 Osteoma Informed consent; Treatment Inappropriate surgery; lack of informed
consent Defense claimed risk of necrosis
with bisphosphonate not well known at the
time of the surgery
Defendant prevailed ($0)
Dec-01 N/A Trial: Dec-04 Salivary gland excision Informed consent, treatment Failure to inform risk chronic dry mouth with
of salivary gland excision
$596,323 ($732,906)
Jan-04 N/A Trial: Oct-90 Oral cancer Treatment Negligent removal of tumor; metastasis,
leading to more extensive surgery
$833,000 ($1,474,269)
Jan-85 Jan-87 Trial: Mar-94 Osteoradionecrosis Treatment Failure to diagnose osteoradionecrosis before
tooth extraction
$2,960,000 ($4,620,097)
Oct-85 N/A Trial: Sep-94 Osteoradionecrosis Treatment; dentist and
hospital
Failure to extract before radiation therapy;
extraction following necrosis; lack of
informed consent; failure to refer
Total $2,900,000 (70% general
dentist; 25% hospital dental center)
Jun-85 N/A Settlement: 1989 Osteoradionecrosis Treatment Failure to take precautions in extraction
following radiation therapy
Settlement: $1,001,308 ($1,867,900)
1985 N/A Trial: Mar-94 Osteoradionecrosis Treatment Extraction of teeth despite knowledge of
prior radiation treatment
$2,960,000 ($4,620,097)
Apr-97 N/A Jan-00 Osteonecrosis, extraction Treatment Incomplete health history; not aware of
radiation for Hodgkin disease
Osteoradionecrosis, mandibular fracture,
septicemia, brain damage, visual loss
following extraction
Hearing pending ($0)
N/A, not available.
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Table II. Summary of medical malpractice cases
Incident date Filing date Mediation/ trial date Primary diagnosis
Malpractice
liability Allegations
Outcome of case (in 2012
dollars)
N/A N/A Settlement: Jan-91 Cancer: jaw Diagnosis Failure to diagnose lump in jaw with history of
lip cancer
Settlement: $225,000
($382,130)
Jul-09 N/A Trial: May-12 Cancer: oral Diagnosis:
Physician and
hospital
Failure to diagnose leukoplakia; progression to
cancer with metastasis Defendant: patient
noncompliant
Fault: 40% plaintiff, 0%
doctor, 40% hospital:
$368,500 ($368,500)
Jan-82 Jan-85 Trial: May-90 Cancer: jaw Diagnosis Failure to diagnose mass in jaw, altered
medical records
Defendant: patient failed to return for
follow-up; did not alter records
$505,000 (893,765)
N/A N/A Trial: Jun-91 Cancer: oral Diagnosis Failure to diagnose; progression of disease $1,200,000 ($2,034,035)
Mar-97 Jan-99 Trial: Jun-01 Cancer: oral Diagnosis Failure to diagnose; progression of disease;
unnecessary radiation; more extensive
surgery
$2,617,000 ($3,418,163)
Oct-87 Jan-91 Trial: Feb-92 Cancer: oral Diagnosis Failure to diagnose metastatic melanoma $1,200,000 ($1,978,478)
Feb-00 Oct-03 Trial: Jun-07 Cancer: oral Diagnosis Failure to diagnose oral complications,
progression of disease; extensive surgery,
permanent feeding tube
$6,400,000 ($7,140,033)
N/A N/A Settlement: Apr-92 Permanent damage to salivary
glands
Diagnosis Misdiagnosis of melanoma as oral cancer,
incorrect treatment
$400,000 ($659,493)
Sep-92 N/A May-99 Cancer: oral Diagnosis Failure to stage and treat cancer $475,000 ($659,517)
N/A N/A Oct-03 Cancer: oral; salivary gland
damage
Diagnosis Failure to diagnose; progression of disease;
radiation damage to salivary glands
Defense prevailed ($0)
Aug-97 to Oct-97 N/A Mar-05 Cancer: Oral Diagnosis Failure to biopsy, delay in diagnosis.
Defendant contended lesions due to a viral
syndrome
Defense prevailed ($0)
December 2002-April 2003 N/A Oct-06 Cancer: oral Diagnosis Delay in diagnosis; more extensive treatment
and associated toxicities
Defense: performed a biopsy at initial
presentation but results were negative
Defense prevailed ($0)
Oct-85 N/A Trial: Sep-90 Cancer: oral Diagnosis Failure to diagnose nodal metastasis Defense prevailed ($0)
Past Medical expenses:
$4000 ($7,079)
Jan-85 Feb-88 Trial: Mar-93 Cancer: oral Prevention:
Physician
and hospital
Failure to prevent mucositis; dental damage $308,433 ($382,132)
N/A N/A Verdict: Mar-02 Cancer: oral Treatment Treatment without cancer staging; radiation
therapy without adequate healing of surgical
ﬂap; multiple facial and leg surgeries
$1,902,178 ($2,445,837)
Jan-00 Jul-01 Verdict: 2002 Cancer: oral and pharyngeal Treatment Failure to provide adequate postoperative care $12,887,000 ($739,340)
-1977 N/A Verdict: Jul-93 Cancer: brain stem Treatment Radiation therapy to wrong side; hearing loss 7
years after treatment due to
osteoradionecrosis
$3,500,000 ($5,602,834)
O
R
A
L
M
ED
IC
IN
E
O
O
O
O
180
E
pstein
et
al.
F
ebruary
2015
T
ab
le
II
.
C
on
tin
ue
d
In
ci
de
nt
da
te
F
ili
ng
da
te
M
ed
ia
tio
n/
tr
ia
l
da
te
P
ri
m
ar
y
di
ag
no
si
s
M
al
pr
ac
tic
e
lia
bi
lit
y
A
lle
ga
tio
ns
O
ut
co
m
e
of
ca
se
(i
n
20
12
do
lla
rs
)
Ja
n-
01
20
06
N
ov
-1
0
C
an
ce
r:
or
al
,
w
ith
lu
ng
an
d
sp
in
al
m
et
as
ta
si
s
T
re
at
m
en
t
F
ai
lu
re
to
re
fe
r
fo
r
ch
em
ot
he
ra
py
;m
et
as
ta
si
s
to
lu
ng
an
d
sp
in
e
D
ef
en
se
pr
ev
ai
le
d
($
0)
N
/A
N
/A
Ja
n-
07
C
an
ce
r:
or
al
T
re
at
m
en
t
F
ai
lu
re
to
ex
ci
se
ad
eq
ua
te
m
ar
gi
ns
du
ri
ng
su
rg
er
y;
re
cu
rr
en
ce
;
ex
te
ns
iv
e
tr
ea
tm
en
t
an
d
ul
tim
at
el
y
de
at
h
D
ef
en
se
pr
ev
ai
le
d
($
0)
F
eb
to
A
pr
-0
5
N
/A
Ju
n-
09
O
st
eo
m
a
In
fo
rm
ed
co
ns
en
t;
tr
ea
tm
en
t
D
ef
en
se
pr
ev
ai
le
d
($
0)
Ja
n-
05
N
ov
-1
2
B
re
as
t
ca
nc
er
an
d
os
te
on
ec
ro
si
s
In
fo
rm
ed
co
ns
en
t;
tr
ea
tm
en
t
F
ai
lu
re
to
re
co
gn
iz
e
ri
sk
of
os
te
on
ec
ro
si
s;
br
ea
ch
of
bi
sp
ho
sp
ho
na
te
im
pl
ie
d
w
ar
ra
nt
y
$1
0.
45
m
ill
io
n
P
er
so
na
l
in
ju
ry
:
pu
ni
tiv
e
ex
em
pl
ar
y
da
m
ag
es
($
10
,0
00
,0
00
)
P
er
so
na
l
in
ju
ry
:
pa
st
pa
in
an
d
su
ff
er
in
g
($
35
0,
00
0)
P
er
so
na
l
in
ju
ry
:
fu
tu
re
pa
in
an
d
su
ff
er
in
g
($
10
0,
00
0)
O
ct
-0
4
N
/A
A
pr
-1
2
O
st
eo
ne
cr
os
is
In
fo
rm
ed
co
ns
en
t:
pr
od
uc
t
lia
bi
lit
y
F
ai
lu
re
to
di
sc
lo
se
ri
sk
of
os
te
on
ec
ro
si
s;
br
ea
ch
of
bi
sp
ho
sp
ho
na
te
im
pl
ie
d
w
ar
ra
nt
y
$2
25
,0
00
($
22
7,
52
1)
N
/A
,
no
t
av
ai
la
bl
e.
OOOO ORIGINAL ARTICLE
Volume 119, Number 2 Epstein et al. 181symptoms are reported.9 Self-report of conﬁdence in
detection of PMEL and HNC are poor in both dentists
and physicians (dentists 37% vs physicians 15%).10
The examination must include cranial nerve examina-
tion, head and neck cervical lymph node examination,
and inspection and palpation of oral soft tissue. How-
ever, only two-thirds of dentists report palpation of
cervical lymph nodes always or usually, and intraoral
palpation was reported in less than one-third of
patients.8
Acute and chronic oral complications of cancer
therapies have been reviewed recently.11 National and
international guidelines for the prevention and man-
agement of oral complications in cancer therapy have
been developed and promulgated by the Multinational
Association for Supportive Care in Cancer and the In-
ternational Society for Oral Oncology and aspects of
oral care supported by the American Society of Clinical
Oncology and the European Society of Medical
Oncology.12 These guidelines are available from the
National Information Clearing House of the National
Institutes of Health and on the National Cancer In-
stitutes of Health website.13 These sources provide
guidance and standards for the prevention and man-
agement of complications and support the need for
multidisciplinary care for patients and survivors of
cancer. Acute oral complications include mucositis,
pain, infection, dry mouth, taste alterations, dental
complications, difﬁculty swallowing, and speech alter-
ations. Extension of treatment-related complications
and ultimate survivorship issues include pain, infection,
dry mouth, bone and soft tissue necrosis, taste change,
dental and periodontal disease, scarring and ﬁbrosis and
limitation of oral tissue, and restriction in jaw and head
and neck movement. Thus, national standards have
been developed for oral care and management
throughout the treatment phase and beyond.
The purpose of this paper is to review the medico-
legal actions summarized in three national legal data-
bases related to HNC and their implications for patient
care by dental and medical providers.MATERIALS AND METHODS
We accessed three legal databasesdLexisNexis,14 JVR
Verdictﬁnder,15 and www.verdictsearch.com.16
The ﬁrst legal database that was accessed was
LexisNexis.14 This database was searched using the
following search terms: “failure to diagnose and or treat
oral cancer,” “osteoradionecrosis” and “biphosphonate
necrosis.” These search terms initially generated 110
results, and these results were screened to eliminate
noneoral cancer cases and defense verdicts. This
resulted in a total of 13 cases that included either set-
tlements or plaintiff verdicts.
ORAL MEDICINE OOOO
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same terms; however, when use of prior search terms
did not return cases, we added additional terms in order
to identify cases in the database based on the search
terms appropriate for the speciﬁc database.
We then searched the legal database JVR Verdict-
ﬁnder.15 This nationwide search covered the 10 years
before the search date of November 15, 2012. Search
terms for this database included “osteoradionecrosis,”
“osteonecrosis,” “bisphosphonate osteonecrosis,”
“pathologic fracture,” “severe rampant dental disease,”
“xerostomia,” “chronic pain,” “death,” “failure to di-
agnose and treat oral cancer,” “delayed referral,” “failure
to prevent osteoradionecrosis, osteonecrosis, bisphosph-
onate osteonecrosis, pathologic fracture, rampant (severe)
dental disease,” “Oral/dental complications of cancer
therapy: toxicity and oral complications of cancer ther-
apy.” This resulted in the identiﬁcation of 27 cases of
settlements or plaintiff verdicts, six of which were elimi-
nated because they were unrelated to the issues addressed
in this study.
The third database searched was www.verdictsearch.
com.16 Initially, a global search of the term “dental
malpractice” was performed to determine the potential
number of cases in the database on this topic. This
yielded 291 total cases. The database was then searched
by the following search terms, and the following
numbers of cases were generated: “dental pathologic
(0 cases),” “caries (5 cases),” “oral cancer (18 cases),”
“osteoradionecrosis (1 case),” “xerostomia (1 case),”
“rampant dental (6 cases)” and “osteonecrosis
(32 cases).” In an attempt to isolate additional related
cases from ones outside the scope of this article, the
following search terms were used with the 291 dental
malpractice cases: “cancer (12 cases),” “toxicity (0
cases)” and “dental caries (1 case).”RESULTS
Forty-one malpractice cases found in the searches of the
legal databases identiﬁed dental providers (Table I), and
23 identiﬁed medical providers (Table II). Outcomes
resulting in zero payment to the plaintiffs were
excluded from the ﬁnancial analysis in this article but
included for analyzing the nature of the allegations
asserted.
Of the cases naming dental providers, 30 cases were
related to alleged delay in diagnosis or misdiagnosis
(Figure 1), 10 cases were related to oral complications,
most commonly due to osteonecrosis, 6 due to issues
related to informed consent, and 5 due to negligent
treatment. (Note: Some of the 41 cases alleged more
than one cause). Eight cases were found in favor of the
defendant. Of the cases where the plaintiff obtained
a recovery, the highest amount recovered was$3,500,000.00. The mean recovery of the 26 cases,
including verdicts and settlements, was $1,033,500.11.
Of the cases naming medical providers (Figure 2), 16
cases were related to alleged delay in diagnosis or
misdiagnosis, 5 to osteonecrosis, and 5 to negligent
treatment errors. (Note: Some of the 22 cases described
more than one alleged cause). Six cases were related to
failure to prevent or effectively manage the oral com-
plications of cancer treatment. Seven cases were in
found in favor of the defendant. Of the cases where the
plaintiff obtained a recovery, the highest amount
recovered was $12,887,000. The mean recovery of the
15 cases, including verdicts and settlements, was
$2,828,639.20.
The search of the legal databases for medical cases
identiﬁed three cases related to the antecedent use of
bisphosphonates and osteonecrosis. These results
included the largest award listed above ($12,887,000
awarded in a products liability action), as well as re-
coveries in the amount of $10,450,000 and $225,000.
DISCUSSION
Patient outcomes and the medicolegal implications of
delayed or missed diagnosis of oral malignant disease
are recognized, as they may result in large damage
claims based on the cost of care, pain, suffering, po-
tential disﬁgurement, lost income, negative impact on
quality of life, and potential loss of life. Oral compli-
cations are of increasing importance in the care of pa-
tients with cancer11 but have received less attention
despite the medicolegal implications identiﬁed in this
article. Legal issues are also impacted by the
completeness and accuracy of the patient records,
which may compound liability issues when the records
are inadequate, incomplete, or altered.
Detection, leading to diagnosis, begins when an ab-
normality is recognized and differentiated from varia-
tions of normal. HNC may present with few, minimal,
and nonspeciﬁc symptoms, and now increasingly with
human papilloma viruseassociated cancer, HNC may
present with lymphadenopathy and occult primary
disease. Patient delay may be due to no or minimal
symptoms, and symptoms and signs must be sufﬁcient
for the patient and the health care provider to recognize
an abnormality even when a coincidental ﬁnding is
made in a routine follow-up visit. Similarly, minor and
nonspeciﬁc symptoms may be overlooked or minimized
by the health care worker. It is well known that the rate
of progression from premalignant conditions to cancer
is not predictable, and this may vary with the lower risk
of cancer progression for PMEL with mild dysplasia or
more advanced and severe cellular changes that may
progress rapidly in some cases once the condition
progresses to SCC. In addition, whether dysplasia of
varying degrees of severity will progress or regress
Fig. 1. Dental malpractice cases.
Fig. 2. Medical malpractice cases.
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Volume 119, Number 2 Epstein et al. 183cannot be predicted. Cellular heterogeneity within and
between tumors further complicates prediction of tumor
behavior. In addition, the histologic diagnosis of
various stages of premalignancy and cancer is at times
subjective17,18 and, like clinical evaluation, requires
the involvement of experienced providers and
diagnosticians.
Recognition of signs and symptoms that may repre-
sent malignant disease in the head and neck are critical
and may be the reason a patient presents to the health
care worker. Variations of normal and ﬂuctuating
symptoms (e.g., mild sensitivity or discomfort) reduce
the probability of a malignant condition, whereas per-
sisting and progressive symptoms must be addressed.
However, oral PMEL and early-stage SCC may often
be asymptomatic or present with minimal and nonspe-
ciﬁc symptoms. More advanced disease may be asso-
ciated with symptoms, including discomfort, local
numbness or tingling, limited movement of the
involved tissue (e.g., lips, tongue, or soft palate), speech
alterations, presence of a mass, an ulcerated lesion and/
or bleeding from the involved site, sore throat, difﬁculty
swallowing, and mass or swelling in the neck, and incases of advanced disease, weight loss may be noted. It
should also be pointed out that sometimes the detection
and diagnosis of HNC is difﬁcult even in the presence
of one or more of these signs and symptoms and even
when the standard of care is met by the dental or
medical professional.
Although, the literature is not clear on the time delay
that may be of signiﬁcance,1-6 delayed diagnosis and
progression in stage of disease is the most common
allegation in HNC malpractice cases identiﬁed in the
legal databases. Failure to diagnose or refer for diag-
nosis is a common factor in litigation.10,19-21 Failure to
recognize past cancer therapy to the region of concern
and the impact this may have upon dental treatment that
may lead to complications also clearly represent po-
tential for malpractice claims.
In a previous report, we identiﬁed example cases to
provide guidance from prior cases of litigation related
to HNC.21 The reasons are multifactorial and include
limitation in training and inexperience in diagnosis of
cancers, and because signs and symptoms may be
nonspeciﬁc, minimal, or subtle and the low disease
prevalence may result in a low index of suspicion.9,22
The changing epidemiology of HNC and oral cancer
among younger people and the expansion of at-risk
populations due to certain forms of human papilloma
virus and immunosuppression are changing the pre-
sentation of disease and altering risk proﬁles.11
Acute and chronic oral complications of disease and
treatment that require prevention and management cross
boundaries between dentistry and medicine. Oncolo-
gists must take action to limit or prevent oral compli-
cations when possible, which requires a close working
relationship with informed and experienced dental
providers and knowledge of guidelines for patient care
that have been established. Failure to recognize this
obligation is seen in a number of cases identiﬁed in this
review of malpractice claims (Tables I and II; Figures 1
and 2). Prevention and management of oral complica-
tions is, however, affected by limited training and
experience in oncology among dental providers, and
similar limitation in the training and experience of
medical providers with regard to oral and dental care.
The treated patient with oral cancer and HNC becomes
a more complex and potentially compromised dental
patient. Oncologists should understand the specialized
nature of the potential oral conditions and be aware that
the training and experience of the dental professional
may be limited and that this may be best managed by
experienced dentists integrated into the oncology
team.23
To achieve an accurate diagnosis, clinicians must
select the most appropriate diagnostic test(s), which
must be conducted and interpreted appropriately. In the
case of biopsy performance, site selection, technique,
ORAL MEDICINE OOOO
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as these may affect the pathologist’s diagnosis.
Furthermore, the interpretation of the biopsy specimen
may also be affected by the level of experience and
training of the pathologist. Interpretations of oral bi-
opsies have shown interrater and intrarater variability in
sign-out diagnoses.17,18 Tissue evaluation may require
special tissue stains and techniques (e.g., ﬂow cytom-
etry, immunohistochemistry, molecular and genetic
analysis, etc.), which may assist or be required to
achieve tissue diagnosis. Additionally, the selection of
diagnostic studies depends on the experience of the
pathologist with regard to head and neck pathology and
the range of testing options available to that person. In
cases where the histopathologic diagnosis is not
consistent with the clinical appearance or behavior of
the lesion, review of the pathology, repeating the bi-
opsy, use of special tissue stains, and/or obtaining other
pathologist’s opinions may be needed. Consideration
should also be given to referral to more experienced
health care providers in such cases. In addition, such
conditions as proliferative verrucous leukoplakia pre-
sent a challenge, as diagnosis is based on clinical
ﬁndings supported by histologic ﬁndings; it cannot be
conﬁrmed on histopathology alone and therefore re-
quires experience in the clinical diagnosis and man-
agement of oral mucosal disease.24 Other tissue
sampling techniques, including exfoliative cytology,
ﬁne-needle aspiration, and core biopsy, which involve
cell collection and diagnostic interpretation, are also
subject to variability in interpretation. Molecular tech-
niques may add information to that obtained in tissue
evaluation and increase the accuracy of the tissue
diagnosis. Given the rapid advances in research and
clinical care, seeking expert referral and newer molec-
ular tests in diagnosis should be considered. Further-
more, additional diagnostic testing may include
imaging (e.g., dental radiography, computed tomogra-
phy, magnetic resonance imaging, positron emission
tomography), which requires interpretation by radiolo-
gists and other health care providers and is subject to
the limitations of the imaging modality chosen and the
variability in the training and experience of the indi-
vidual interpreting the images.
Delay in diagnosis and the resultant progression of
disease are common allegations in malpractice cases
related to HNC.21,25 In approximately half the legal
cases found involving HNC, biopsies were allegedly
indicated but not performed.25 In 2001, the average cost
of defending medical malpractice claims in the United
States was $28,801, and the median cost of jury awards
was $1 million in 2003.26 In our review, the mean re-
covery where plaintiffs were successful was
$1,033,500.11 for dental cases and $2,828,693.20 for
the medical or products liability cases.Lydiatt20 reviewed jury outcomes for 50 cases
involving HNC from 1984 to 2000 using the Westlaw
(St. Paul, Minnesota) legal database. In this review,
defendants won in 42% of cases, plaintiffs prevailed in
32%, and 26% of cases reached a settlement.20 In our
review of the legal databases, we focused on those
cases where the plaintiffs obtained a recovery. The most
common allegations were failure to diagnose, failure to
perform a biopsy, failure to provide a referral, and
complications associated with cancer treatment. In pa-
tients under 47 years of age, the average award was
$755,824, and in those older than 47 years, awards
averaged $495,417.20 Of 26 cases that went to trial, 8
were won by the defendant, and those in favor of the
plaintiff had a mean award of just over $2,000,000.
Those cases settled by mediation had a much lower
mean award of approximately $475,000.
Lower levels of awards were reported in 86% of the
cases where alleged delay was less than 3 months and
40% where the alleged delay was more than 3
months.20 As in other studies, common allegations were
failure to perform a biopsy and failure to provide a
referral.20,21,25,26 Forty-ﬁve percent of the 50 legal
cases were found against dentists, and 60% of these
cases alleged that the dentist did not have a biopsy
performed.20 In a study of cases involving antral and
sinonasal cancers, similar ﬁndings were reported.27
Defendants prevailed in 62% of cases, with a median
award of $650,000. Younger patients prevailed at a
higher rate than did older patients (50% vs 35%), and
men had a higher median award than did women ($1
million vs $314,000).27
Health care providers must recognize an abnormality
and take steps to achieve a deﬁnitive diagnosis or refer
the patient to a more experienced or specialist dental or
medical care provider in order to avoid medicolegal
risk, even though the impact of delay in diagnosis and
treatment is not well documented. The impact of delay
is affected by the biologic variability of the tumor, host
or individual factors, and referral bias. Nevertheless,
from a legal perspective, a delay in diagnosing or
referring a patient could be costly. The elements typi-
cally required in malpractice cases include showing a
breach of the standard of care and that the injury or
negative effect resulted from that deviation.20,21,27-29
Although the facts of a case determine the outcome,
intangible factors, including such issues as sympathy
for the plaintiff or the family, may also be considered
despite instructions given by courts to juries to disre-
gard such feelings of sympathy from their consideration
of the case.25 However, it is important to note that a
poor outcome in oncology is not necessarily evidence
of malpractice, as outcomes are associated with indi-
vidual ﬁndings, such as the stage of the disease or the
biology of the tumor.
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reaching proportions that threaten the delivery of health
care.25 The most common allegation of malpractice
claims in patients with HNC is delay in diagnosis.
Often, plaintiffs are younger than those expected to be
at risk. In addition to delays in diagnosis, allegations
can also include increased morbidity and possibly
poorer treatment outcomes.20,25
Our review showed that lack of prevention, recog-
nition, and management of oral complications
following current national standards of care may lead to
medicolegal action. In such cases, these were the factors
that were the basis of 31% of cases involving oncolo-
gists and 29% of cases involving dental providers.
These complications included mucositis, xerostomia
(and related complications), and osteonecrosis of the
jaw. These cases emphasize the need for prevention,
early detection, and appropriate management best pro-
vided by functioning oncology teams that include
experienced medical and dental providers.
Study limitations include practical limitations with
regards to the availability of data, and therefore, the
results are only reﬂective of the available data. Despite
the vast resources used by the searched databases, many
cases may not make their way into these databases.
Court records are yet to be universally electronic or
made available to these databases. Additionally, set-
tlements are, more often than not, kept conﬁdential.
Therefore, there are likely a large number of cases not
represented in the data considered by this article. These
cases have the potential to signiﬁcantly impact the
values and percentages resulting from the data consid-
ered in our analysis.
CONCLUSIONS
The reported knowledge, training, and experience of
dental and medical providers may impact the recogni-
tion, detection, and diagnosis of oral premalignant and
malignant disease and in the recognition, prevention,
and treatment of oral complications of cancer therapy.
In addition, the separation of medicine and dentistry in
the practical aspects of delivery of care, including in
payment and reimbursement systems, increases the
barriers in obtaining medically necessary oral care and
also impacts research in multidisciplinary disease and
treatment with broad impact on quality of life and cost
of care. Undergraduate medical training, dental
training, graduate and residency training and continuing
education, and in-service care models are needed to
overcome these challenges.19,27,30-32 Risk management
goals for early detection to prevent delays in the diag-
nosis, prevention, and management of oral complica-
tions of cancer therapy may help prevent subsequent
litigation. Health care providers must be diligent in
maintaining an index of suspicion, developing a set ofdifferential or possible diagnoses, and taking steps in
obtaining a deﬁnitive diagnosis, including possible
referral to others. They must also have a clear under-
standing of the oral complications of surgical, medical,
and radiologic treatment modalities and facilitate pre-
vention and management of complications, best
ensured by integrated comprehensive medical and
dental oncology care teams.REFERENCES
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